Publications by authors named "P B Snyder"
Background: The potential diagnostic value of plasma amyloidogenic beta residue 42/40 ratio (Aβ42/Aβ40 ratio), neurofilament light (NfL), tau phosphorylated at threonine-181 (p-tau181), and threonine-217 (p-tau217) has been extensively discussed in the literature. We have also previously described the association between retinal biomarkers and preclinical Alzheimer's disease (AD). The goal of this study was to evaluate the association, and a multimodal model of, retinal and plasma biomarkers for detection of preclinical AD.
View Article and Find Full Text PDFChronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. Genome wide association studies have identified the G1 and G2 variants in the apolipoprotein L1 (APOL1) gene as major contributors to a subtype of proteinuric kidney disease now referred to as APOL1-mediated kidney disease (AMKD). We hypothesized that inhibition of APOL1 could have therapeutic potential for this genetically-defined form of kidney disease.
View Article and Find Full Text PDFArticle Synopsis
- Subjective visual impairment (VI) is linked to cognitive performance in both cognitively unimpaired (CU) older adults and patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD).
- The study used the NEI-VFQ-25 and a neuropsychological test to explore this relationship, finding that CU adults had a positive link between subjective VI and visuospatial abilities.
- Results suggest that subjective VI complaints could serve as indicators for specific cognitive decline areas like attention, processing speed, and executive function in older individuals.
Purpose: This study aimed to evaluate the total macular thickness as well as the thickness of the inner and outer retinal layers in patients with Parkinson's disease. It also aimed to verify the correlation of these parameters with motor symptoms and cognitive function.
Methods: A total of 46 eyes of 23 patients with Parkinson's disease and 40 eyes of 20 healthy controls were included in the study.
Article Synopsis
- Inotersen is an approved drug for hereditary transthyretin-mediated amyloidosis (hATTR), evaluated through various nonclinical safety studies to assess its effects and risks.
- In studies involving Tg.rasH2 mice and Sprague Dawley rats, no treatment-related tumors were found, although some proinflammatory effects and kidney issues were noted.
- Overall, the data suggest that while there are side effects linked to Inotersen, there is insufficient evidence to classify it as carcinogenic, particularly concerning its relevance to human health.